Described herein are polymeric nanoparticles that comprise {[(1R,25)-1-({[(1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]-dioxadiazacyclo-nonadecino[11,12-b]quinoxalin-8-yl]carbonyl}amino)-2-vinylcylopropyl]carbonyl}(cyclopropylsulfonyl)azanide, (i.e., grazoprevir), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles.

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula

TABLE-US-00001 (SEQIDNO:1) X.sub.1X.sub.2X.sub.3X.sub.4X.sub.5GVX.sub.6AKAGVX.sub.7NX.sub.8FKSESY (I) (SEQIDNO:2) (X.sub.9).sub.nGVX.sub.10AKAGVX.sub.11NX.sub.12FKSESY (II) (SEQIDNO:3) YKX.sub.13LRRX.sub.14APRWDX.sub.15PLRDPALRX.sub.16X.sub.17L (III) (SEQIDNO:4) YKX.sub.18LRR(X.sub.19).sub.nPLRDPALRX.sub.20X.sub.21L (IV) (SEQIDNO:5) IKLSGGVQAKAGVINMDKSESM (V) (SEQIDNO:6) IKLSGGVQAKAGVINMFKSESY (VI) (SEQIDNO:7) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQIDNO:8) GVQAKAGVINMFKSESY (VIII) (SEQIDNO:9) GVRAKAGVRNMFKSESY (IX) (SEQIDNO:10) GVRAKAGVRN(Nle)FKSESY (X) (SEQIDNO:11) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQIDNO:12) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQIDNO:13) YKSLRRKAPRWDAYLRDPALRPLL (XIII) wherein X.sub.1 to X.sub.21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

A pharmaceutical composition and method reduces statin-related side effects, including myalgia, myositis, myopathy, and myonecrosis. The composition comprises at least one HMG-CoA reductase inhibitor (statin) and vitamin D. The composition may comprise one or more excipient. The pharmaceutical composition is adapted to decrease side effects of said HMG-CoA reductase inhibitors. The excipient may comprise one or more excipient delivery agent providing immediate release, sustained release, extended release and/or combination thereof of said HMG-CoA and/or vitamin D. The amount of the vitamin D may be fixed or variable. A method of treating hyperlipidemia is provided comprising an orally administered pharmaceutical composition having at least one HMG-CoA reductase inhibitor and vitamin D. Preferably, the pharmaceutical composition is administered once per day, via oral, nonoral, transdermal and/or injection drug delivery.

The present disclosure relates to cannabinoid compositions used in combination with stem cell therapies. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.

This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

Compositions useful for delivery of active pharmaceutical ingredients (APIs) and active nutraceutical ingredients (ANIs) to a targeted tissue or a targeted cell of a mammalian body, comprising a complex of at least one nanoparticle; at least one API; the API is contained by the nanoparticle; at least one nutraceutical ligand, the nutraceutical ligand is configured to specifically bind to the targeted tissue or a targeted cell; wherein the API or the ANI is activated at the targeted tissue or at a targeted cell by the mediation of the nutraceutical ligand.

A pepino mosaic virus (PepMV) carrier comprising a PepMV particle that has been modified to carry an imaging agent or anticancer agent is described. The PepMV carrier can be used in a method of targeting cancer cells and tissue by administering it to a subject. Cancer tissue targeted by the PepMV carrier can be imaged using an imaging agent, or treated using an anticancer agent.

Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240? C. to 280? C.

Nanomaterials fabricated to pharmaceutical dosage forms are disclosed. The nanomaterials are useful to provide a plurality of analysis to the dosage form. Consequently, the nanomaterials provide a means to perform quality testing on a continuous basis throughout the supply chain, including the cold chain whereby manufacturers and distributors can achieve greater product integrity and longer shelf life and ultimately minimize cost. The end user benefits in obtaining the highest quality drugs at the time of need.